Memphasys

Memphasys Equity

The The Equity of Memphasys (MEM.AX) as of Oct 19, 2026 is 4.21 M AUD. In the previous year, The Equity was 5.37 M AUD — a change of -21.52% (lower).

Equity

4.21 MAUD

YoY

-21.52%

Last updated:

In 2026, Memphasys's equity was 4.21 M AUD, a -21.52% increase from the 5.37 M AUD equity in the previous year.

The Memphasys Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
6.07 M AUD
Jan 1, 2020
9.76 M AUD
Jan 1, 2021
8.61 M AUD
Jan 1, 2022
7.65 M AUD
Jan 1, 2023
7.38 M AUD
Jan 1, 2024
6.84 M AUD
Jan 1, 2025
5.37 M AUD
Jan 1, 2026
4.21 M AUD
The Memphasys Equity history
YEAREquityYoY
4.21 MAUD-21.52%
5.37 MAUD-21.49%
6.84 MAUD-7.41%
7.38 MAUD-3.42%
7.65 MAUD-11.16%
8.61 MAUD-11.78%
9.76 MAUD+60.68%
6.07 MAUD+81.15%
3.35 MAUD-933.23%
-402,240.00AUD-127.22%
1.48 MAUD+97.92%
746,591.00AUD-175.20%
-992,848.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Memphasys's Equity

Memphasys's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Memphasys's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Memphasys's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Memphasys's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Memphasys’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Memphasys stock

The Equity of Memphasys is 4.21 M AUD in 2026.

The Equity of Memphasys changed from 5.37 M AUD to 4.21 M AUD, representing a -21.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Memphasys since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Memphasys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Memphasys

All Key Metrics — Memphasys